Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride users have a very low risk of mental health issues, but those with hair loss may have slightly higher anxiety and depression.

Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.

SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.

Men with male pattern baldness are more likely to have benign prostatic hyperplasia.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.

Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.

Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.

Male pattern baldness may be an early sign of noncancerous prostate enlargement.

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.

Urologists should screen for mental health issues before and during finasteride treatment.

Finasteride is linked to sexual dysfunction, especially in younger men using it for hair loss.

Finasteride alone increases suicide risk, but combining it with other treatments reduces this risk.

Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.

Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.

Finasteride use is linked to a higher risk of obstructive sleep apnea.

Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.

Dutasteride and finasteride don't raise erectile dysfunction risk.

Hair loss is linked to higher prostate-specific antigen levels and urinary symptoms, likely due to age.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.